Serological Markers of Hepatitis B Virus and Cytomegalovirus Infections in Norwegians with Coagulation Factor Defects

Overview

Journal Blut

Specialty Hematology

Date 1990 Feb 1

PMID 2154272

Authors

H Rollag

S A Evensen

S S Froland

A Glomstein

Affiliations

Soon will be listed here.

Abstract

The prevalence of serological markers for present and past hepatitis B virus (HBV) infection and antibodies against cytomegalovirus (CMV) among Norwegians with coagulation factor defects was examined in serum samples collected before virus-inactivated coagulation concentrates came into use. Sera collected in 1985/86 from 324 of 377 (86%) registered persons with such defects were available. Three persons were chronic carriers of HBsAg. The prevalence of HBV antibodies was 28% compared with about 5% in the general population. The highest prevalence rate was found among patients with severe haemophilia A (44%) and in patients with haemophilia B (39%). The prevalence of anti-CMV antibodies was 75% which is similar to that found in the general Norwegian population.

References

Tabor E, Purcell R, London W, Gerety R . Use of and interpretation of results using inocula of hepatitis B virus with known infectivity titers. J Infect Dis. 1983; 147(3):531-4. DOI: 10.1093/infdis/147.3.531. View

Helske T . Carriers of hepatitis B antigen and transfusion hepatitis in Finland. Scand J Haematol Suppl. 1974; 22:1-65. View

Ulstrup J, Figenschou K . Frequency of hepatitis-B infections. Lancet. 1972; 2(7785):1035. DOI: 10.1016/s0140-6736(72)92452-x. View

Cheeseman S, Sullivan J, Brettler D, Levine P . Analysis of cytomegalovirus and Epstein-Barr virus antibody responses in treated hemophiliacs. Implications for the study of acquired immune deficiency syndrome. JAMA. 1984; 252(1):83-5. View

Monif G, Daicoff G, FLORY L . Blood as a potential vehicle for the cytomegaloviruses. Am J Obstet Gynecol. 1976; 126(4):445-8. DOI: 10.1016/0002-9378(76)90636-0. View

. Immunologic and virologic status of multitransfused patients: role of type and origin of blood products. By the AIDS-Hemophilia French Study Group. Blood. 1985; 66(4):896-901. View

Skar A, Hoddevik G . Prevalence of cytomegalovirus antibodies in Norwegian kidney-transplant recipients and their living donors. A comparative study of two different methods. Acta Pathol Microbiol Immunol Scand B. 1984; 92(1):1-5. DOI: 10.1111/j.1699-0463.1984.tb02786.x. View

Rickard K, Batey R, Dority P, Johnson S, Campbell J, Hodgson J . Hepatitis and haemophilia therapy in Australia. Lancet. 1982; 2(8290):146-8. DOI: 10.1016/s0140-6736(82)91105-9. View

Evatt B, Gomperts E, McDougal J, Ramsey R . Coincidental appearance of LAV/HTLV-III antibodies in hemophiliacs and the onset of the AIDS epidemic. N Engl J Med. 1985; 312(8):483-6. DOI: 10.1056/NEJM198502213120805. View

10.

Hurlen B, JONSEN J, Aas E . Viral hepatitis in dentists in Norway. Acta Odontol Scand. 1980; 38(5):321-4. DOI: 10.3109/00016358009033599. View

11.

Stein S, Evatt B, McDougal J, Lawrence D, Holman R, Ramsey R . A longitudinal study of patients with hemophilia: immunologic correlates of infection with HTLV-III/LAV and other viruses. Blood. 1985; 66(4):973-9. View

12.

Evensen S, Ulstrup J, Skaug K, Froland S, Glomstein A, Rollag H . HIV infection in Norwegian haemophiliacs: the prevalence of antibodies against HIV in haemophiliacs treated with lyophilized cryoprecipitate from volunteer donors. Eur J Haematol. 1987; 39(1):44-8. DOI: 10.1111/j.1600-0609.1987.tb00162.x. View